Figure 1.

Baricitinib is detectable in plasma and tissues from SARS-CoV-2-infected RMs but has no impact on viral kinetics

(A) Study design; 8 RMs were infected intranasally and intratracheally with SARS-CoV-2, and at 2 days after infection, 4 RMs began daily baricitinib administration (4 mg). Longitudinal collections performed are indicated in circles.

(B and C) Concentration of baricitinib 24 h after dosing in plasma (6 days after infection closed symbol; 8 days after infection open symbol) (B) and at necropsy in upper and lower lungs of baricitinib-treated SARS-CoV-2-infected RMs (C).

(D and E) Daily cage-side assessment and physical examination scores (D) and changes in body weight from baseline (E) in baricitinib-treated (blue symbols; n = 4) and untreated (red symbols; n = 4) SARS-CoV-2-infected RMs.

(F) Longitudinal pulse oximetry readings.

(G–J) After SARS-CoV-2 inoculation, nasal, throat, bronchoalveolar lavages (BALs), and rectal swabs were collected, and viral loads were quantified by qRT-PCR.

(K) Viral loads in tissues measured at necropsy (10–11 days after infection).

Abbreviation is as follows: Ct, cycle threshold. Different symbols represent individual RMs. Thick lines represent the average of the baricitinib-treated (blue lines) and untreated (red lines) groups. Bars in (B), (C), and (K) represent the average of the treated and untreated groups. Statistical analysis was performed using a non-parametric Mann-Whitney test.

See also Figures S1 and S2A and Tables S1, S2, and S3.